Related Experiment Video

Updated: Jun 5, 2026

Sub-acute Cerebral Microhemorrhages Induced by Lipopolysaccharide Injection in Rats
06:39

Sub-acute Cerebral Microhemorrhages Induced by Lipopolysaccharide Injection in Rats

Published on: October 17, 2018

Brain microbleeds and Alzheimer's disease: innocent observation or key player?

Charlotte Cordonnier1, Wiesje M van der Flier

  • 1Univ Lille Nord de France, CHU Lille, EA 1046. Pôle de neurologie F-59000 Lille, France. charlotte.cordonnier@chru-lille.fr

Brain : a Journal of Neurology
|January 25, 2011
PubMed

Insights

Brain microbleeds, small lesions in Alzheimer's disease (AD), may link amyloid and vascular theories. Understanding these microbleeds is crucial for AD pathophysiology, clinical course, and therapeutic strategies.

Area of Science:

  • Neurology
  • Neuroimaging
  • Pathophysiology

Background:

  • Brain microbleeds are identified as hyposignal lesions on gradient echo MRI sequences.
  • These microbleeds are increasingly recognized for their potential role in Alzheimer's disease (AD) pathogenesis.

Purpose of the Study:

  • To review current data on brain microbleeds in Alzheimer's disease.
  • To elucidate the clinical significance and underlying pathology of these lesions.
  • To identify limitations in current knowledge for clinical trial design.

Main Methods:

  • Literature review of existing studies on brain microbleeds in AD.
  • Analysis of data linking microbleeds to AD pathophysiology and clinical outcomes.
  • Evaluation of the impact of microbleeds on therapeutic strategies and clinical trials.

Main Results:

  • Brain microbleeds may bridge the amyloid cascade and vascular hypotheses of AD.
  • These lesions can influence the clinical progression and presentation of Alzheimer's disease.
  • Microbleeds have potential implications for treatment strategies and the design of clinical trials.

Conclusions:

  • Brain microbleeds are significant markers in Alzheimer's disease, potentially linking key pathological pathways.
  • Further research is needed to fully understand their role and to optimize clinical trial designs.
  • Addressing microbleeds may offer novel therapeutic avenues for Alzheimer's disease.

More Related Videos

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...